Fundz

LivaNova Appoints Stefano Folli as President of Cardiopulmonary Business Unit

PUBLIC · LIVNMay 21, 2026

Position

President

Company

LivaNova

Stefano Folli
LondonBiotechnologyHealth CareMedicalMedical Device

Description

LivaNova PLC has announced the appointment of Stefano Folli as the incoming President of its Cardiopulmonary Business Unit, effective June 1. Folli will succeed Franco Poletti, who is retiring on July 31, and will work closely with him during the transition period.

Quick answer

LivaNova Appoints Stefano Folli as President of Cardiopulmonary Business Unit (May 21, 2026). LivaNova is based in London, England, United Kingdom.

Who is the new President at LivaNova?
LivaNova named Stefano Folli President, announced May 21, 2026.
What did LivaNova announce on May 21, 2026?
LivaNova PLC has announced the appointment of Stefano Folli as the incoming President of its Cardiopulmonary Business Unit, effective June 1. Folli will succeed Franco Poletti, who is retiring on July 31, and will work closely with him during the transition period.
What does LivaNova do?
LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering...
Where is LivaNova based?
LivaNova is based in London, England, United Kingdom.

Source: Fundz verified event record.

Who to call at LivaNova, and when

A new leader at LivaNova brings new priorities and often new vendors. The first weeks are when they listen.

  • An alert the day LivaNova raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at LivaNova, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at LivaNova. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

LivaNova

Location

London, England, United Kingdom

About

LivaNova PLC is a global medical technology company built on nearly five decades of experience and a relentless commitment to provide hope for patients and their families through medical technologies, delivering life-changing solutions in select neurological and cardiac conditions. Headquartered in London, LivaNova employs approximately 2,900 employees and has a presence in more than 100 countries for the benefit of patients, healthcare professionals, and healthcare systems worldwide.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment LivaNova changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

Ahmet
Likely contact at this company
••••••••@••••••••

See Ahmet's verified email →

Create an account to reveal verified emails
Predictive Intelligence
Strategic

ML-powered predictions for LivaNova's next move

Learn about Strategic plan

LivaNova changed its leadership. Fundz had it the day it was filed, with the decision-maker at the company attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.